Details

Autor(en) / Beteiligte

• Zhou, Na
• Zhang, Chuan‐Tao
• Lv, Hong‐Ying
• Hao, Chen‐Xing
• Li, Tian‐Jun
• Zhu, Jing‐Juan
• Zhu, Hua
• Jiang, Man
• Liu, Ke‐Wei
• Hou, He‐Lei
• Liu, Dong
• Li, Ai‐Qin
• Zhang, Guo‐Qing
• Tian, Zi‐Bin
• Zhang, Xiao‐Chun

Titel

Concordance Study Between IBM Watson for Oncology and Clinical Practice for Patients with Cancer in China

Ist Teil von

• The oncologist (Dayton, Ohio), 2019-06, Vol.24 (6), p.812-819

Ort / Verlag

Hoboken, USA: John Wiley & Sons, Inc

Erscheinungsjahr

2019

Link zum Volltext

Quelle

Wiley Online Library Journals Frontfile Complete

Beschreibungen/Notizen

• Background IBM Watson for Oncology (WFO), which can use natural language processing to evaluate data in structured and unstructured formats, has begun to be used in China. It provides physicians with evidence‐based treatment options and ranks them in three categories for treatment decision support. This study was designed to examine the concordance between the treatment recommendation proposed by WFO and actual clinical decisions by oncologists in our cancer center, which would reflect the differences of cancer treatment between China and the U.S. Patients and Methods Retrospective data from 362 patients with cancer were ingested into WFO from April 2017 to October 2017. WFO recommendations were provided in three categories: recommended, for consideration, and not recommended. Concordance was analyzed by comparing the treatment decisions proposed by WFO with those of the multidisciplinary tumor board. Concordance was achieved when the oncologists' treatment decisions were in the recommended or for consideration categories in WFO. Results Ovarian cancer showed the highest concordance, which was 96%. Lung cancer and breast cancer obtained a concordance of slightly above 80%. The concordance of rectal cancer was 74%, whereas colon cancer and cervical cancer showed the same concordance of 64%. In particular, the concordance of gastric cancer was very low, only 12%, and 88% of cases were under physicians choice. Conclusion Different cancer types showed different concordances, and only gastric cancers were significantly less likely to be concordant. Incidence and pharmaceuticals may be the major cause of discordance. To be comprehensively and rapidly applied in China, WFO needs to accelerate localization. ClinicalTrials.gov Identifier: NCT03400514. Implications for Practice IBM Watson for Oncology (WFO) has begun to be used in China. In this study, concordance was examined between the treatment recommendation proposed by WFO and clinical decisions for 362 patients in our cancer center, which could reflect the differences of cancer treatment between China and the U.S. Different cancer types showed different concordances, and only gastric cancers were significantly less likely to be concordant. Incidence and pharmaceuticals may be the major causes of discordance. To be comprehensively and rapidly applied in China, WFO needs to accelerate localization. This study may have a significant effect on application of artificial intelligence systems in China. 摘要 背景。IBM 沃森肿瘤 (WFO) 可以使用自然语言处理程序来评估结构化和非结构化格式的数据，我们已在中国开展使用。它可以提供各种基于证据的治疗选择并将它们划分为三个类别，以提供治疗决策支持。本研究旨在检验 WFO 提出的治疗建议与我们癌症中心的肿瘤医生制定的实际临床决策之间的一致性，这可以反映出中美之间的癌症治疗差异。 患者和方法。在 2017 年 4 月至 2017 年 10 月期间，WFO 输入了来自 362 名癌症患者的回顾性数据。按照三种类别提供 WFO 建议:建议、以供考虑和不建议。通过对比 WFO 与多学科肿瘤委员会建议的治疗决策，我们对一致性进行了分析。当肿瘤医生的治疗决策在 WFO 中属于建议或以供考虑的类别时，即表示实现了一致性。 结果。卵巢癌显示出最高的一致性，为 96%。肺癌和乳腺癌取得了略高于 80% 的一致性。直肠癌的一致性为 74%，而结肠癌和宫颈癌显示出相同的一致性，同为 64%。特别值得注意的是，胃癌的一致性非常低，仅为 12%，88% 的病例均由医生选择。 结论。不同的癌症类型显示出不同的一致性，只有胃癌明显不太可能一致。发病率和药物可能是导致不一致的主要原因。为了实现在中国的全面、快速应用，WFO 需要加速本地化。ClinicalTrials.gov 标识符:NCT03400514。 对临床实践的提示:我们现已在中国开始使用 IBM 沃森肿瘤 (WFO)。在本研究中，我们检验了针对我们癌症中心的 362 名患者的 WFO 治疗建议与临床决策之间的一致性，这可以反映出中美之间的癌症治疗差异。不同的癌症类型显示出不同的一致性，只有胃癌明显不太可能一致。发病率和药物可能是导致不一致的主要原因。为了实现在中国的全面、快速应用，WFO 需要加速本地化。本研究可能对人工智能系统在中国的应用产生重大影响。 Using the updated version of IBM Watson for Oncology, this study explored the concordance of the suggested therapeutic regimen between Watson and physicians in China. This article reports results and suggests some similarities and differences between the East and West in the treatment of cancer.